(+/-) CPP, an NMDA receptor antagonist, blocks the induction of commissural-CA3 LTP in the anesthetized rat.
Commissural CA3-CA3 (cCA3) long-term potentiation (LTP) was investigated in the anesthetized rat treated with the highly selective NMDA-receptor antagonist D,L-3[(+/-)-2-carboxypiperazin-4-yl]- propyl-1-phosphonic acid (CPP). Intraperitoneal injections of CPP did not significantly affect baseline test responses for either field EPSP slope or amplitude measures but did reduce LTP in a dose-dependent manner, with 3.2 mg/kg as the lowest effective dose. EPSP variability following tetanization was also significantly reduced in both the 3.2 mg/kg and 10.0 mg/kg groups. We interpret these results to suggest that a 3.2 mg/kg dose of CPP may be sufficient for studying the behavioral effects of this NMDA receptor antagonist.
Hernandez
R V
RV
Department of Psychology, University of California, Berkeley 94720.
Derrick
B E
BE
Rodriguez
W A
WA
Martinez
J L
JL
D000758:Anesthesia; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D004594:Electrophysiology; D005071:Evoked Potentials / Q000187:drug effects; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects*; D017774:Long-Term Potentiation / Q000187:drug effects*; D008297:Male; D010879:Piperazines / Q000494:pharmacology*; D017966:Pyramidal Cells / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
D010879:Piperazines; D016194:Receptors, N-Methyl-D-Aspartate; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid